Posts by: Iqra Mumal

News

Inhibiting IL-23, a molecule involved in inflammation, was not found to be clinically meaningful to treat ankylosing spondylitis, according to the results from a Phase 2 trial. The study, ... Read more

July 2, 2018July 2, 2018

Eli Lilly Announces Positive Results from Its 2nd Phase 3 Trial of Ixekizumab

News

Treatment with Eli Lilly’s monoclonal antibody Taltz (ixekizumab) significantly improved the signs and symptoms of ankylosing spondylitis in patients participating in a Phase 3 clinical trial, results show. The study, called COAST-W (NCT02696798), met ... Read more

May 15, 2018May 15, 2018

Patient Support Services Linked with Better Health Outcomes in Ankylosing Spondylitis Patients

News

Ankylosing spondylitis patients who receive tailored, personalized services, such as care coach calls, have a higher probability of achieving controlled disease within six to 18 months, a study shows. The ... Read more

May 7, 2018May 7, 2018

Ankylosing Spondylitis Patients More Likely to Develop COPD, Researchers Find

News

Patients with ankylosing spondylitis are more likely to develop a lung disorder known as chronic obstructive pulmonary disease (COPD) compared to the rest of the population, according to researchers. ... Read more

April 11, 2018April 11, 2018

Only 30% of Those with Inflammatory Back Pain Develop Spondyloarthritis, Study Finds

News

Just 30 percent of people who begin experiencing inflammatory back pain — an early symptom of spondyloarthritis — develop the disease, a study reports. The research, “Clinical evolution of ... Read more

November 29, 2017November 29, 2017

Two Canadian Provinces Add Biosimilar Erelzi to Treatment Plan for Inflammatory Diseases

News

Sandoz recently announced the addition of Erelzi (etanercept) to the public drug plan in the Canadian provinces of British Columbia and Prince Edward Island for the treatment of multiple inflammatory diseases ... Read more

November 8, 2017November 8, 2017

Novartis’ Cosentyx Shows Very Little Radiographic Progression in Ankylosing Spondylitis Patients

News

Novartis recently reported that long-term radiographic data from a clinical trial showed that treatment of ankylosing spondylitis (AS) with Cosentyx (secukinumab) resulted in no disease progression in a vast majority ... Read more

October 18, 2017October 18, 2017

Enbrel Treatment Leads to Early Reparative Response in Patients with Non-Radiographic Axial Spondyloarthritis

News

Patients with non-radiographic axial spondyloarthritis (nr-axSpA) treated with Amgen‘s Enbrel (etanercept), which blocks tumor necrosis factor (TNF), experience a very early reparative response to therapy, new research shows. The ... Read more

Posts by: Iqra Mumal

Iqra Mumal

Blocking IL-23 Not Sufficient to Treat Ankylosing Spondylitis, Phase 2 Trial Finds

Eli Lilly Announces Positive Results from Its 2nd Phase 3 Trial of Ixekizumab

Patient Support Services Linked with Better Health Outcomes in Ankylosing Spondylitis Patients

Ankylosing Spondylitis Patients More Likely to Develop COPD, Researchers Find

Only 30% of Those with Inflammatory Back Pain Develop Spondyloarthritis, Study Finds

Two Canadian Provinces Add Biosimilar Erelzi to Treatment Plan for Inflammatory Diseases

Novartis’ Cosentyx Shows Very Little Radiographic Progression in Ankylosing Spondylitis Patients

Enbrel Treatment Leads to Early Reparative Response in Patients with Non-Radiographic Axial Spondyloarthritis

Pin It on Pinterest